Inland Northwest s Best: Gerry Lindgren to Mark Few, the region has produced college sports legends spokesman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spokesman.com Daily Mail and Mail on Sunday newspapers.
(Reuters) - Novavax Inc said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccin.
Novavax Inc said on Monday it
would pursue full approval of its COVID-19 vaccine in the second
half of this year and forecast total revenue of between $4
billion and $5 billion for 2022. . | February 28, 2022
By Carl O Donnell, Francesco Guarascio and Neil Jerome Morales (Reuters) - Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government s vaccine rollouts told Reuters. Novavax said it has completed delivery of only around 10 million vaccine doses so far, but is moving as quickly as possible to ship its contracted supplies for this quarter. Some shipments have been held up by regulatory processes and are waiting in a distribution warehouse to go to healthcare providers, Novavax spokesperson Amy Speak said. Gaithersburg, Maryland-based Novavax, which had never launched a product, had ambitions to provide a vaccine for the world, promising to deliver its shots by mid-2021. When the tiny company missed 2021 targets, buyers turned to rivals including Pfizer Inc/BioNTech SE, Moderna In